We plan to begin our evaluation in September 2020. Our objective is to determine whether the DoD has mitigated the risks of interruptions to the pharmaceutical supply chain, due to the DoD's reliance on foreign suppliers. We will look at the extent of the DoD’s reliance on foreign suppliers, supply chain risk management strategies, pharmaceutical reserves, and pharmaceutical quality assurance programs. We may expand the objective and scope during the course of the evaluation if we find program oversight issues that require immediate management attention. We will also consider suggestions from management on additional or revised objectives for this evaluation.